{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:14:12Z","timestamp":1777914852677,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Palliative Medicine"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dyspnea is common in interstitial lung disease (ILD) patients and often refractory to conventional treatment. Little is known regarding the safety of systemic morphine in ILD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study is to evaluate the safety of a single subcutaneous morphine injection and to determine the recommended dose of morphine for alleviating dyspnea in ILD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We conducted a dose-escalation Phase I study for investigating the recommended dose of a single subcutaneous morphine injection to alleviate dyspnea in ILD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting\/Subjects:<\/jats:title>\n                    <jats:p>\n                      Eligible subjects were ILD inpatients with dyspnea at rest who were refractory to conventional dyspnea treatment. The morphine doses used were 1\u2009mg and 2\u2009mg in cohort 1 and cohort 2, respectively. The primary endpoint was dose-limiting toxicity, which was defined as (1) respiratory depression, that is, 30% reduction of respiratory rate and 10 Torr increase of PaCO\n                      <jats:sub>2<\/jats:sub>\n                      compared with baseline; (2) hypotension, that is, 20% reduction of systemic blood pressure compared with baseline and presentation of hypotension-related symptoms; or (3) grade 3, 4, or 5 treatment-emergent adverse events graded by Common Terminology Criteria for Adverse Events (version 4).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of six patients were enrolled, with three patients each in cohorts 1 and 2. No dose-limiting toxicities were observed; three patients experienced worsened somnolence, but no patients experienced sedation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We conclude that 2\u2009mg of morphine has a tolerable safety profile in ILD patients with dyspnea, and can be tested in further clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jpm.2018.0272","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T11:48:42Z","timestamp":1534852122000},"page":"1718-1723","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Morphine for Refractory Dyspnea in Interstitial Lung Disease: A Phase I Study (JORTC-PAL 05)"],"prefix":"10.1177","volume":"21","author":[{"given":"Yoshinobu","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan."},{"name":"Clincal Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Morita","sequence":"additional","affiliation":[{"name":"Palliative and Supportive Care Division, Seirei Mikatahara General Hospital, Hamamatsu, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tempei","family":"Miyaji","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Osaka National Hospital, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Nursing, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tokoro","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan."},{"name":"Clincal Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Iwase","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Saitama Medical University, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Clincal Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200503-483OE"},{"key":"e_1_3_3_3_2","first-page":"772","volume-title":"Idiopathic Pulmonary Fibrosis, Lung Biology in Health and Disease","author":"Coultas DB HR","year":"2004","unstructured":"Coultas DB HR: Epidemiology of idiopathic pulmonary fibrosis. In: Lynch JPIII, (ed.). Idiopathic Pulmonary Fibrosis, Lung Biology in Health and Disease. New York: Marcel Dekker; 2004, p. 772."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00000812"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1127"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207439"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e3282ff6336"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.1.9704130"},{"key":"e_1_3_3_10_2","first-page":"CR405","article-title":"Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis","volume":"8","author":"Baddini Martinez JA","year":"2002","unstructured":"Baddini Martinez JA, , Martinez TY, , Lovetro Galhardo FP, et al.: Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit, 2002; 8:CR405\u2013410.","journal-title":"Med Sci Monit"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2008.01359.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.09.005"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2007000200004"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.6.1627"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.17509540"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201501-034OC"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.11.939"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.523"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.11.021"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1191\/0269216305pm998oa"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.5362"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Matsuda Y Maeda I Tachibana K et al.: Low-Dose Morphine for Dyspnea in Terminally Ill Patients with Idiopathic Interstitial Pneumonias. J Palliat Med 2017.","DOI":"10.1089\/jpm.2016.0432"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e3283392b51"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.04.026"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3402\/ecrj.v3.30629"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-9-199311010-00007"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2015.05.014"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2107138"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3918\/jsicm.17.73"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-12-941"}],"container-title":["Journal of Palliative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jpm.2018.0272","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jpm.2018.0272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jpm.2018.0272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:03:04Z","timestamp":1777654984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jpm.2018.0272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1089\/jpm.2018.0272"],"URL":"https:\/\/doi.org\/10.1089\/jpm.2018.0272","relation":{},"ISSN":["1096-6218","1557-7740"],"issn-type":[{"value":"1096-6218","type":"print"},{"value":"1557-7740","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}